Drupal.behaviors.print = function(context) {window.print();window.close();}>
Sequenom Preliminary Full-year 2012 Revenues Grow 59 Percent to $89M
January 07, 2013
Sequenom Preliminary Full-year 2012 Revenues Grow 59 Percent to $89M
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Sequenom's CEO 'Puzzled' by Illumina's Buy of Verinata, Lays out 2013 Goals at JP Morgan
January 10, 2013 / GenomeWeb Daily News
Sequenom Collects 18K Samples for MaterniT21 Plus in Q3, Expects to Bill for Over 50K Tests in 2012
November 14, 2012 / Clinical Sequencing News
Non-invasive T21 Testing Space Abuzz as Firms Jockey for Share of $1B Market, Battle over IP
April 11, 2012 / GenomeWeb Daily News
As MaterniT21 Drives Spike in Diagnostic Revenue, Sequenom Predicts 25K Tests Sold in 2012
March 14, 2012 / Clinical Sequencing News
MaterniT21 Doubles Sequenom's Revenues; Firm Inks Deal with Blue Cross Blue Shield Association
May 15, 2013 / Clinical Sequencing News